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ABSTRACT
Glycoconjugate vaccines use protein carriers to improve the
immune response to polysaccharide antigens. The protein com-
ponent allows the vaccine to interact with T cells, providing
a stronger and longer-lasting immune response than
a polysaccharide interacting with B cells alone. Whilst in theory
the mere presence of a protein component in a vaccine should
be sufficient to improve vaccine efficacy, the extent of improve-
ment varies. In the present review, a comparison of the perfor-
mances of vaccinesdevelopedwith andwithout a protein carrier
are presented. The usefulness of analytical tools for macromole-
cular integrity assays, in particular nuclear magnetic resonance,
circular dichroism, analytical ultracentrifugation and SEC
coupled to multi-angle light scattering (MALS) is indicated.
Although we focus mainly on bacterial capsular polysaccharide-
protein vaccines, some consideration is also given to research on
experimental cancer vaccines using zwitterionic polysaccharides
which, unusually for polysaccharides, are able to invoke T-cell
responses and have been used in the development of potential
all-polysaccharide-based cancer vaccines.
A general trend of improved immunogenicity for glycoconju-
gate vaccines is described. Since the immunogenicity of
a vaccine will also depend on carrier protein type and the way
in which it has been linked to polysaccharide, the effects of
different carrier proteins and production methods are also
reviewed. We suggest that, in general, there is no single best
carrier for use in glycoconjugate vaccines. This indicates that the
choice of carrier protein is optimally made on a case-by-case
basis, based on what generates the best immune response and
can be produced safely in each individual case.
Abbreviations: AUC: analytical ultracentrifugation; BSA:
bovine serum albumin; CD: circular dichroism spectroscopy;
CPS: capsular polysaccharide; CRM197: Cross Reactive
Material 197; DT: diphtheria toxoid; Hib: Haemophilius influ-
enzae type b; MALS: multi-angle light scattering; Men:
Neisseria menigitidis; MHC-II: major histocompatibility com-
plex class II; NMR: nuclear magnetic resonance spectroscopy;
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OMP: outer membrane protein; PRP: polyribosyl ribitol phos-
phate; PSA: Polysaccharide A1; Sa: Salmonella; St.:
Streptococcus; SEC: size exclusion chromatography; Sta:
Staphylococcus; TT: tetanus toxoid; ZPS: zwitterionic polysac-
charide(s).
Introduction
Polysaccharides are attractive antigens to use as vaccines because they are
often key exposed components of the bacterial capsule and tumours (Hütter
& Lepenies, 2015; Zimmermann & Lepenies, 2015). The capsule protects
bacterial cells from phagocytes (Finlay & Falkow, 1997) and is located on the
cell surface, readily available to interact with cells of the adaptive immune
system. In a similar way, glycans on the surface of cancer cells are useful
strategic targets for developing cancer vaccines. B cells are able to bind to
polysaccharides that possess suitable complementary binding sites, typically
repeating patterns that cross-link multiple receptors (Maglione et al., 2014).
The process depends on interaction with other immunogenic molecules
such as lipopolysaccharides, to show that the non-self-polysaccharide is also
a risk to the host body (Bretscher & Cohn, 1970; Snapper & Mond, 1996).
Once activated, the B cell releases IgM isotype antibody (Maglione et al.,
2014; Snapper & Mond, 1996), a pentameric antibody which gives it high
avidity (Niles, Matsuuchi, & Koshland, 1995) but low affinity as no affinity
maturation occurs (Eisen & Siskind, 1964).
A major histocompatibility complex class II (MHC-II) bound antigen can
interact with CD4 + T cells and become activated (Janeway, 1989), causing
isotype switching and affinity maturation in B cells. The B cells will now
make high affinity IgG antibodies rather than IgM (Guttormsen et al., 1999),
and memory cells will develop for a longer-lived immune response (Avci &
Kasper, 2010). Without MHC-II binding, no T cells become involved and so
these advantages of longer-lived immunity do not occur, and there is a less
marked improvement on re-inoculation. This is a major issue when trying
to use polysaccharides as vaccines which in general do not bind to MHC-II
(see, for example, Zimmermann & Lepenies, 2015).
Protein antigens are taken up by antigen-presenting cells and digested.
MHC II proteins fold in the endoplasmic reticulum where a complex is
formed with a protein known asinvariant chain (Ii) (Roche & Cresswell,
1990). This precursor molecule is then transported to late endosomal
compartments where the invariant chain is cleaved by cathepsin proteases.
However, a short fragment is retained by the binding groove of MHC II. The
fragment can be exchanged with higher affinity molecules in endocytic
compartments, which will be derived from proteolytically degraded
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antigens. Often a human leukocyte antigen initially binds and acts as
a catalyst for further binding with pathogen antigens. The specific antigen
that is exchanged depends on the charge distribution, geometry and hydro-
phobicity of the binding groove, as well as the catalyst currently in the
binding groove (Wieczorek et al., 2017). The binding groove itself is highly
variable as it is produced from multiple gene locations and codominantly
expressed alleles (Janeway, Travers, Walport, & Shlomchik, 2001). Ideally
there would be a simple method to predict this binding to allow more
comprehensive control in vaccine design. However, while progress has
been made developing bioinformatic algorithms to predict antigen binding
to MHC II, these remain imperfect (Lyngaa et al., 2014; Paul et al., 2013).
Antigen fragments are presented in the MHC-II on the cell surface where
they can interact with CD4 + T cells to activate B cells triggering differentia-
tion and clonal expansion. Therefore, unlike most polysaccharide antigens,
the secondary response to infection is improved due to the presence of high
levels of IgG, making proteins more useful as vaccines.
Unfortunately, for pathogens such as encapsulated bacteria, the only
available surface antigens are polysaccharides (Kasper, 1986). As they gen-
erally cannot be processed using the MHC-II and T cells, with the exception
of zwitterionic polysaccharides (ZPS), these are not optimal molecules to
use as vaccines (Avci & Kasper, 2010; Guttormsen et al., 1999). Fortunately,
there is a way to improve the immunogenicity of a polysaccharide antigen.
Glycoconjugate vaccines add the positive traits of a protein antigen to
a polysaccharide antigen by covalently binding the two together. When
taken up by antigen-presenting cells, the conjugate molecule will be
digested, and covalently-linked fragments containing both polysaccharides
and proteins can bind to the MHC-II (Avci, Li, Tsuji, & Kasper, 2011). This
is presented to T cells, triggering isotype switching and B cell differentiation
into memory cells, thus acting as a good vaccine.
An alternative method may be available in which instead the vaccine
triggers the production of carbohydrate specific CD8 + T cells, which being
cytotoxic can kill malfunctioning body cells directly, which would be of
immense importance in combatting cancer. Tumour marker gangliosides,
sialic acid-containing glycosphingolipids with extracellular polysaccharide
head groups, are expressed at high levels on cancer cells (Daniotti, Lardone,
& Vilcaes, 2016; Daniotti, Vilcaes, Torres Demichelis, Ruggiero, &
Rodriguez-Walker, 2013; Saragovi & Gagnon, 2002). This carbohydrate
head at the cell surface is readily available to interact with cells of the
immune system, and therefore acts as an antigen for cancer cells and so is
a potential cancer vaccine target. However, a number of possible examples
proved to be poor vaccines, as they were either insufficiently immunogenic
or did not provide clinical benefits (Chapman et al., 2000; Kawashima et al.,
2003; Kim et al., 2011; Kirkwood et al., 2001; Ragupathi et al., 2003, 2000). In
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these instances, the vaccines worked by triggering the production of anti-
bodies. However, Tong et al. (2019) have produced synthetic antigens of
tumour marker gangliosides linked to polyamidoamine scaffolds to illicit
responses in γδ T cell receptor and CD8+ phenotypes that seem to be
therapeutic.
To produce a glycoconjugate vaccine, each part is produced individually
then conjugated into one molecule. Only the polysaccharide part is unique
for a given vaccine. Usually one of a small group of proteins is used, usually
inactivated toxins, ‘toxoids’. Toxins are produced by some pathogenic cells,
which can be used as bio-factories (Chung et al., 2016; Nielsen, 1967). They
are inactivated, often with formaldehyde (Nielsen, 1967), and are shown
historically as strongly antigenic and safe, such as tetanus toxoid (TT), in use
as a vaccine since 1924. It is also possible to use comparatively new non-
toxic mutants of TT such as Cross Reactive Material 197 (CRM197) rather
than diphtheria toxoid (DT) (Giannini, Rappuoli, & Ratti, 1984; Rappuoli,
1983). However safe a toxoid is known to be, use of a non-toxic mutant is
inherently safer to produce than a toxoid and alleviates risk of a toxoid that
is not fully inactivated, or from which formaldehyde has not been removed.
Pathways to conjugation
Figure 1 shows 3 pathways to glycoconjugate vaccine production (Jones,
2012). In Pathway (a) the glycoconjugate vaccine is produced by coupling
monofunctional oligosaccharides (after depolymerisation of the parent
polysaccharide) or bifunctional oligosaccharides at low coupling efficiency,
and either through direct attachment to the carrier protein or indirect
attachment (through a linker). Pathway (b) involves activation of higher
molecular weight polysaccharides (without depolymerisation) and conjuga-
tion through non-specific chemistry to multiple carrier proteins to give
a very high molecular weight complex of >1MDa size and (c) involving
reduced mass polysaccharides with multiple activations coupled to LPS-
depleted outer membrane protein (OMP) vesicles.
Although the bulk of protein carriers are related to toxins, other examples
are known. As any antigen that is perceived as non-self will be sufficient to
induce an immune response, there is a vast array of known proteins at our
disposal to use as carrier. For example, keyhole limpet hemocyanin has been
used as a carrier for glycoconjugate vaccines against Candida albicans (Liao
et al., 2016) and even some cancers with distinct molecular markers (Song,
Zheng, Liu, Zhou, & Ye, 2017). Bovine serum albumin (BSA) is a well-
characterised protein that has also been used, for example against
Aspergillus fumigatus (Komarova et al., 2015). All these proteins can be
produced by growing cell cultures to high cell density and then purifying the
protein. This is particularly easy for toxoids, as the toxin is naturally secreted
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by pathogens (Chung et al., 2016; Nielsen, 1967). However, it is also possible
to apply cloning strategies in order to place the encoding gene of interest
into a less pathogenic organism.
The polysaccharide portion of the glycoconjugate has in the past been
more problematic to produce. Unlike proteins, polysaccharides are not
produced from a direct set of instructions that give an identical structure
every time. Instead, they are produced enzymatically, which gives variation
or ‘polydispersity’. This depends on the local kinetics, thermodynamics, and
relative proportions of subunits and enzymes during the polysaccharide
Figure 1. The three pathways to glycoconjugate vaccine production. The ellipsoid(s) shown in
green represent(s) a carrier protein (popularly tetanus toxoid protein, diptheria toxoid protein or
CRM197), the black zig-zags represent the capsular polysaccharide, and the white arrow the
activated end region. (a) Glycoconjugates produced from oligosaccharides with a single attach-
ment site, or limited crosslinking through two sites. (b) Glycoconjugates produced by multiple
activation sites on high mass polysaccharides and multiple attachments to the carrier protein,
producing crosslinked network. (c) Glycoconjugates produced by attachment of ‘size-reduced’
polysaccharides to outer membrane protein vesicles through multiple attachment sites. From
Jones (2012) and reproduced by permission of the Royal Society of Chemistry.
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production. This means that the easiest means by which to generate antigens
that are similar to the wild type pathogen is to purify the polysaccharides
from a bacterial culture. However, as with proteins, this is undesirable, as it
sometimes requires large pathogen cultures to be grown. It is possible that
small fragments could be synthesised in vitro, but even if the epitope has the
same sequence it will also need the same three-dimensional structure to
interact correctly with immune receptors. Nonetheless advances have been
made in synthesis and fractionation making it possible to produce poly-
saccharide fractions which are near-monodisperse. Greater polydispersity
arises from the variability in the extent of conjugation, rendering molecular
weight (molar mass) distribution and other characterisation methods parti-
cularly important (Harding, Abdelhameed, Gillis, Morris, & Adams, 2015).
Once the components have been produced, they need to be linked together
covalently. However, just as the synthesis of polysaccharides results in polydis-
persity, this step can also introduce variation. On the surface of each molecule
there are a number of functional groups with the potential to generate a link
under the right conditions.Oneway of limiting this polydispersity is to target the
formation of specific bonds, as described by Adamo et al. (2014).
Once a vaccine is made, it must be tested to ensure it is of acceptable quality.
Each part, as well as the link between them, must be stable. Of the two
components, the most important to remain stable is the polysaccharide, as this
must be able to mimic accurately the structure of the target antigen, while the
protein only needs to be recognised as non-self. The link between the two
molecules also needs to remain intact, although there must be an acceptable
level of breakdown. As the entire vaccine must be produced on an industrial
scale, care should be taken to predict manufacturing issues to prevent problems
later in development. In this regard, physicochemicalmethods have beenproven
to be important in assaying the molecular integrity of conjugated vaccines.
Physico-chemical checks on the molecular integrity and stability
following a production process
Besides traditionally used gel permeation chromatography or size exclusion
chromatography (SEC) a number of physico-chemical techniques have been
shown to be particularly useful as tools formonitoringmacromolecular integrity
after production/processing. High field nuclear magnetic resonance (NMR)
spectroscopy has been shown to provide an important check on the chemical
integrity of products after the industrial production of glycovaccines, and
follows WHO (World Health Organisation) recommendations. NMR provides
a routine release test for identity and testing conformity for the bulk mono-
valent, blended, activated and conjugated polysaccharide component in con-
jugates (Berti & Ravenscroft, 2015), and examples are quoted below.
A complementary method to NMR is circular dichroism spectroscopy (CD)
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which canmonitor secondary structure changes in the carrier protein before and
after conjugation processing.
Another technique which is becoming increasingly important is analytical
ultracentrifugation (AUC) (Harding et al., 2015), now recognised as a gold
standard technique for assessing the molecular integrity and freedom from
aggregation of monoclonal antibody preparations, particularly at high concen-
tration, and is a matrix-free analytical tool, avoiding problems of non-inertness.
A combination of sedimentation velocity and sedimentation equilibriummeth-
ods from the AUC, reinforced by complementary methods such as SEC-MALS
and viscometry are providing (i) absolute molar mass (molecular weight)
information (mainly through the weight average molar mass, Mw) (ii) hetero-
geneity information either through the polydispersity index (Mz/Mw orMw/Mn)
, whereMz andMn are the z- and number- average molar masses respectively,
and/or alsomolarmass or sedimentation coefficient distributions (Figure 2) (iii)
the overall conformation or shape of the carrier proteins (Figure 3) and (iv)
conformational flexibility (in terms of persistence length or power-law para-
meters) of the glycoconjugate and the constituent polysaccharides (Figure 4).
Table 1 shows the change in persistence length (a measure of flexibility) and the
mass per unit length of theHaemophilus influenzaeType b (Hib) polysaccharide
after activation and complexation with TT protein.
These methods can also provide interaction information: self-assembly and
reversibility, aggregation phenomena (together with other methods like
dynamic light scattering (Harding et al., 2015) andpossible complex interactions
with other molecules such as plasma proteins.
The above discussion gives a snapshot of the power of analytical tools in
assessing macromolecular integrity of the vaccines after production. Before
presenting further observations on research into glycoconjugate vaccine design
and production, the following section on zwitterionic capsular polysaccharides
(ZPS) considers an exception to the general idea that polysaccharides are unable
to bind to MHC-II and thereby elicit long-term immunity. Because of their
ability to invoke long-lived T-cell based immunity, ZPS have been exploited as
carriers to explore the development of all-carbohydrate vaccines, particularly in
the field of cancer vaccine development. The following section details the
characteristics of some of these exceptional ZPS (with particular emphasis on
bacterial capsular examples), how they activate T cells and how they have been
used in glycoconjugate cancer vaccine research to date.
Zwitterionic capsular polysaccharides
Unlike most known naturally-occurring carbohydrate structures (which are
either negatively charged or uncharged, and which are unable to activate
T cells), some glycans possessing dual or zwitterionic charge motifs which
appear to be able to activate the traditional MHC-II route to activate T cells
BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS 99
without the assistance of a carrier protein (Cobb & Kasper, 2005; Cobb,
Wang, Tzianabos, & Kasper, 2004). Characteristically, these zwitterionic
glycans possess both positive (such as free amine) and negative (such as
carboxylate or phosphate) centres within a repeating molecular unit
(Tzianabos, Onderdonk, Rosner, Cisneros, & Kasper, 1993; Tzianabos,
Wang, & Lee, 2001). This shows a similarity to the repeating structure of
peptides, which also contain amine and carboxylate groups, suggesting it is
the interaction of these charged groups with theMHC II binding groove that
allows ZPS to bind. A diverse range of bacteria produce ZPS including type 1
Streptococcus (St.) pneumoniae (the SP1 polysaccharide capsule) (Velez,
Figure 2. Heterogeneity/purification determinations using analytical ultracentrifugation (a)
sedimentation coefficient distribution plots g(s) vs s showing continuous but unimodal dis-
tributions at different concentrations of a Streptococcal pneumonia SP5 capsular polysaccharide
preparation. From Harding et al. (2012) and reproduced with permission from Elsevier. (b)
sedimentation coefficient distribution plot (corrected for diffusive effects) c(s) vs s of a tetanus
toxoid preparation showing the presence of dimer (up to 14%) at higher concentration. (c) the
corresponding molar mass distribution c(M) vs M for the tetanus toxoid preparation. From
Abdelhameed et al. (2012) and reproduced by permission of Elsevier. (d) molar mass distribu-
tion f(M) vsM from sedimentation velocity of a large Hib PRP-TT conjugate for a plausible range
of the conformation parameter b using the Extended Fujita approach of Harding et al. (2011).
The size and distribution of the assembly would suggest a ‘model c’ (Figure 1c) type of assembly
of Jones (2012). From Abdelhameed et al. (2016) and reproduced by permission of the Nature
Publishing Group.
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Lewis, Kasper, & Cobb, 2009), Staphylococcus (Sta.) aureus (the CP8 poly-
saccharide) (O’Riordan & Lee, 2004), andMorganella morganii (the O-chain
antigen) (Young et al., 2011). Also, see the review of Neff et al. (2016) which
gives examples from intestinal bacteria. However, the most intensively
studied example of capsular bacterial ZPS is the polysaccharide A1 (PSA)
from Bacteroides fragilis (Figure 5). PSA averages over 100 kDa in size,
equivalent to more than 100 repeating units with both positive and negative
charged groups.
B. fragilis is an obligately anaerobic bacteriumwhich forms part of the natural
human gutflora.However, it is also implicated (because it is themost commonly
isolated bacterium) in formation of abscesses that result from secondary peri-
tonitis arising due to surgery and bowel wounds (Kasper et al., 1977). The
immune response that leads to abscess formation involves both innate and
adaptive systems. The contribution from the adaptive immunity response
depends on activation of CD4+ T cells. In particular, the capsular polysaccharide
(CPS) complex of B. fragiliswith PSA is needed for activating the CD4+ αβT cell
receptor (TCR)-carrying T cells that are required for abscess formation
(Tzianabos et al., 1993). Indeed, PSA elicits a clonal expansion of a subset of
suppressive CD45RBlowCD4+ effector memory T cells and thus a highly specific
CD4+ T cell response (Johnson, Jones, & Cobb, 2015a). It is also a toll-like
receptor 2 (TLR-2) agonist (Wang et al., 2006).
The original suggestion of the involvement of T cells comes from several
lines of compelling evidence reviewed by Cobb and Kasper (2005). The
broad mechanism by which polysaccharides such as PSA activate T cells was
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Figure 3. (a) Conformational ‘power law’ plot from SEC-MALS for a capsular polysaccharide from
Streptococcus pneumoniae SP1. The slope or Mark-Houwink-Kuhn-Sakurada parameter a = 0.8,
corresponds to a flexible coil polysaccharide. From Harding et al. (2012) and reproduced by
permission from Elsevier (b) Plot of mass per unit length ML versus persistence length Lp
evaluation for the Hib PRP-native capsular polysaccharide. The plot yields Lp ∼ 7.0 × 10−7 (cm)
and ML ∼ 3.8 × 109 (g.mol−1.cm−1) at the minimum target (error) function (indicated by the
white cross). From Abdelhameed et al. (2016) and reproduced by permission from the Nature
Publishing Group.
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first described by Cobb et al. (2004), who showed that ZPSs are first
processed to low molar mass carbohydrates through a nitric acid-based
mechanism and then presented to T cells that recognise the MHC/ZPS
complex with αβTCRs, through the MHC II endocytic pathway. This was
a ground-breaking finding, since it was believed at that time that only
peptides (not polysaccharides) elicit T cell activation via MHCII antigen
presentation; indeed, the work suggested a fundamental shift in the MHCII
presentation paradigm (Cobb et al., 2004). The immunological events that
Figure 4. Ellipsoidal (prolate) representation from hydrodynamic analysis of the conformation
of monomeric tetanus toxoid protein using the program ELLIPS1 (García de la Torre & Harding,
2013). The protein is shown to be asymmetric with an axial ratio ~ 3. Coincidentally this appears
to reproduce the ‘guessed’ cartoon representation given earlier by Astronomo and Burton
(2010). Reproduced from Abdelhameed et al (2010) by permission from Elsevier.
Table 1. Values for the mass per unit length ML and the
persistence length Lp from global hydrodynamic analysis (com-
bination of SEC-MALS, AUC and viscosity of Hib capsular poly-
saccharide, before and after activation and conjugation with
tetanus toxoid protein (Abdelhameed et al., 2016).
Sample 10−7 ×ML (g.mol
−1.cm−1) 107 × Lp (cm)
PRP-native 380 ± 50 7.0 ± 1.0
PRP-ADH 600 ± 50 7.0 ± 1.2
PRP-TT 1070 ± 50 4.5 ± 0.3
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Figure 5. The molecular structure of B. fragilis PSA showing (A) one tetrasaccharide repeating unit
(and the chemical modifications required to abolish the negatively-charged free amine (red) and the
negatively-charged carboxylate (blue) groups); (B) NMR spectroscopy-derived average solution
structure (double image for stereo view) which highlights the right-handed helical conformation
(taken from Kreisman et al., 2007). Reproduced by permission from Oxford University Press.
BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS 103
result in abscess formation comprise: (1) activation of antigen-presenting
cells (as the ZPS antigens are endocytosed) which in turn produces TNF-α
and (2) activation of T cells produces cytokines and chemokines that
amplify the response and recruit PMNs to the site of infection.
In addition to its dual charge, another unusual characteristic of PSA is
that it adopts a stable extended helical conformation in solution with two
repeating units per turn and a pitch of 20 Å, as revealed using total
correlated spectroscopy and nuclear Overhauser spectroscopy NMR spec-
troscopy (NOESY) (Figure 2(b)). The carboxylate lies in repeated grooves
every 15 Å whilst the amine groups lie on the outer surface of the glycan
(Wang, Kalka-Moll, Roehrl, & Kasper, 2000). Whilst Cobb et al. (2004)
established that oxidative processing of PSA to fragments of < 15 kDa is
required in order to obtain successful MHCII presentation, another study
by Kalka-Moll et al. (2000) demonstrated that fragments less than ~5 kDa
exhibit severely reduced T-cell activation activities. These collective find-
ings suggested that the epitope is more complex than merely one repeating
unit and could involve a conformational component. When this possibility
was investigated by Kreisman, Friedman, Neaga, and Cobb (2007), it was
found that the functional epitope from PSA requires a specific conforma-
tion that is stabilised by adjacent repeating units, as well as the zwitterionic
charge. These researchers interrogated the conformation of PSA using far-
UV CD. Intriguingly the CD spectra confirmed a helical conformation and
a similarity to the spectrum of myoglobin possessing a spectral minimum
at 225 nm (but no dual minima characteristic of alpha helices) and
a spectral maximum at approximately 205 nm (Figure 6), characteristic
of a helical character, and bearing no resemblance to spectra of control
non-helical carbohydrates or dextran polysaccharides that exhibit no opti-
cal activities in this wavelength range.
Interestingly, the CD spectra of ozone-cleaved PSA exhibited progressive
loss of helical nature (revealed as shallowing of spectral peaks/maxima and
minima) as smaller sized fragments were analysed. PSA fragments of 1 kDa
(one repeating unit) or smaller exhibited no helical character at all. When
these different sized fragments were compared for their ability to bind to
MHCII protein, it was fragments in the 3–30 kDa range that exhibited
maximum MHCII binding.
Fragment sizes greater than this bound only modestly toMHCII molecules
whilst fragments less than this exhibited poor or no binding. The fragments
in this size range also retained their helical character, suggesting conforma-
tion was important. Indeed, the authors suggest that the MHCII binding
maximum correlated with the dominant fragment size of 3 kDa (three
repeating units of the PSA structure) which may be larger than the twelve
amino acid residues claimed previously for proteins. However, later studies
claimed that the α-helical structural characteristic may not play as
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a significant role in immune activation after all. Experiments in which PSA
was used as a carrier to the tumour-associated carbohydrate antigen/hapten
Thomsen-nouveau (Tn = alpha-D-GalNAc-OSer/Thr) to make an entirely
polysaccharide based glycoconjugate vaccine resulted in retained T-cell
mediated immune responses (De Silva et al., 2012), but less α-helical con-
formation (Trabbic, De Silva, & Andreana, 2014). However, although helicity
does indeed appear to be reduced at 217 nm, nevertheless the spectra indicate
that a detectable level of helicity still remained in the conjugate (Figure 7).
Since the discovery by Cobb et al. (2004) that PSA is able to prompt T-cell
mediated immune responses, there have been successful applications of this
knowledge towards development of all-carbohydrate vaccines, especially
cancer vaccines (2012; De Silva, Wang, Chidley, Appulage, & Andreana,
2009; Nishat & Andreana, 2016; Trabbic et al., 2014), and regarding poten-
tial strategies for preventing inflammation using PSA-experienced T cells
(Johnson, Jones, & Cobb, 2015b, 2018), highlighting the considerable future
potential of using ZPS to control immune responses.
Comparison of glycoconjugate and polysaccharide vaccines
The act of conjugating a polysaccharide to a protein may alter some aspects
of its structure, and its effect on the immune system. For this reason,
wherever possible, our review includes comparisons of unconjugated poly-
saccharide vaccines with glycoconjugate vaccines in which the same anti-
genic molecules have been used. This has previously been reviewed in
a meta-analysis by Mitchell, Kelly, Pollard, and Trück (2014), which focused
on the mechanism of action of each vaccine in terms of which immune
system cells were stimulated by each vaccine. The results generally show that
immediately after vaccination, glycoconjugate vaccines show an almost
Figure 6. Effect of the size of PSA on its structural conformation and function. (a) overlaid
Superdex-75 elution characteristics of ozone-cleaved PSA samples; (b) CD spectra of ozone-
cleaved PSA, showing the progressive loss of helical character as more ozone-mediated breaks
are introduced. Full-length PSA is shown at 0 min and exhibits greatest helicity; the smallest
fragments are in 90-min incubated samples in which the shallow spectra indicate loss of
helicity; and (c) PSA binding to MHCII protein, measured by comparison with a conventional
peptide antigen. Colour coding of fragment sizes are retained through all panels. Taken from
Kreisman et al. (2007). Reproduced by permission from Oxford University Press.
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identical response to polysaccharide vaccines. However, they also found that
upon a second vaccination, in the majority of cases a stronger response was
seen in the groups that had received glycoconjugate vaccines. This is con-
sistent with theories that glycoconjugate vaccines stimulate B memory cell
development.
Two other studies investigated vaccines to Hib using polyribosyl ribitol
phosphate (PRP) as the polysaccharide antigen. PRP is a CPS, and in both
studies it was compared on its own and conjugated to CRM197. First,
Rothstein et al. (1991) tested different combinations of conjugated/uncon-
jugated vaccines on 7- to 15-month old infants with inoculation performed
three times. Their findings showed that if all three vaccinations used the
conjugated vaccine, or if only the last one was replaced with pure poly-
saccharides, the responses gave similar mean antibody levels. These levels
were only reduced if two of the three inoculations were replaced with
polysaccharide only. This suggests that polysaccharide vaccines may not
always be inappropriate for use as booster vaccinations. Steinhoff et al.
(1991) looked specifically at the effect of the vaccine on individuals immu-
nocompromised by HIV. The population studied were split into four groups
depending on severity of infection (HIV-, HIV+, asymptomatic HIV+, and
Wavelength (nm)
Figure 7. CD spectra obtained for PSA (dark blue spectrum), the Tn-PSA conjugate (turquoise)
and the Tn amino-oxy sugar (sky blue). Adapted from Trabbic et al. (2014). Reproduced by
permission of the Royal Society of Chemistry.
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AIDS). It was found that the conjugate vaccine gave a three-fold increase in
antibody titre over the pure polysaccharide vaccine unless infection had
progressed to AIDS, at which point they responded poorly to both vaccina-
tions. This suggests that glycoconjugate vaccines may be more suitable for
use in moderately immunocompromised patients.
Commercially available Neisseria menigitidis (Men) vaccination typically
include CPS from serotypes A, C, W, and Y, all conjugated to CRM197. This
vaccine was used in the following three studies. Jacobson et al. (2013)
studied the persistence of immunity after 5 years with either polysaccharide
or conjugate vaccines. It was found that while the polysaccharide vaccine
gave a ‘less robust’ response, it was still adequately protective. This suggests
that whilst a conjugate vaccine may have increased protection, it is not
always necessary, as the polysaccharide vaccine may still be protective.
However, this does not take into account how the response may vary
between different groups (e.g. immunocompromised) and the paper sug-
gests that the response may wane to unsafe levels beyond the five years
tested. Ramasamy et al. (2014) attempted to explain the differences observed
in antibody titre observed after testing conjugated versus polysaccharide
vaccine. It found that the polysaccharide vaccine gave better protection
against serotype C strains, whilst the conjugate vaccine gave better protec-
tion against strains belonging to serotype W. The differences may be due to
a lower titre of polysaccharide C conjugated to the CRM197 protein.
However, the mechanism by which the response to serotype W is reduced
in the pure polysaccharide vaccine is unclear, although it is suggested that
there may be some sort of negative feedback mechanism present when
polysaccharide vaccines are used. This may be explained by O’Connor
et al. (2017), who found that as well as being less effective at eliciting
a response, polysaccharide vaccines might take a role in actively depleting
B memory cells when used as a booster vaccine, a mechanism that may also
explain the findings of Rothstein et al. (1991).
Borja-Tabora et al. (2015) andHolme et al. (2015) studied a meningococcal
vaccine (Men) with the serotypes A, C,W and Y polysaccharides either linked
to TT as a glycoconjugate or as a polysaccharide-only vaccine. Holme et al.
(2015) examined immediate differences between the two vaccines, while
Borja-Tabora et al. (2015) studied the difference in the persistence of immu-
nity after 5 years. Both studies found that antibody titres were higher and
persisted in a greater number of patients when they were inoculated with the
conjugate rather than polysaccharide-only vaccine.
All comparative studies of conjugated versus unconjugated vaccines
against St. pneumoniae used CRM197 as the carrier protein. In each case,
a 23-valent polysaccharide vaccine was compared to either a 7- or 10-valent
conjugate, with comparisons being drawn only for those serotypes that were
present in both vaccines. Simple comparisons of the effectiveness of
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conjugated and unconjugated vaccines were performed for specific popula-
tions. Jackson, Gurtman, van Cleeff, Frenck et al. (2013) showed that in
people aged 60–64, increased antibody titres were seen for the majority of
serotypes analysed when the conjugate vaccine was used. Similarly, in
a Japanese population aged over 80, a higher titre was seen with the con-
jugate vaccine (Namkoong et al., 2015). While in this case all vaccines were
safe, there was a slight increase in swelling/redness from the conjugate
vaccine. While this was mild, it is interesting to note that an increase in
side effects seems to be linked to an increase in response. In patients with
systemic lupus erythematosus, both conjugate and polysaccharide vaccines
for pneumonia-causing St. pneumoniae were found to be safe, but neither
was superior in terms of the protection they provided (Grabar et al., 2017).
It has been shown that booster vaccinations may play a significant role in
improving vaccination protection success of the frail hospitalised elderly
against St. pneumoniae (MacIntyre et al., 2014). It was found that immedi-
ately after vaccination with a 7-valent conjugate vaccine (PCV7) there was
a significant increase in titre of antibodies against serotypes V, and 23F
strains, whilst the 23-valent polysaccharide vaccine (23vPPV) had increased
titres for serotypes 3, 19F and 19A strains. No major benefit of one vaccine
over the other was seen, as all vaccines were protective initially. If a booster
polysaccharide vaccination was administered to the conjugate vaccine
group, antibody titres were increased for serotypes 6A, 9V, 18C and 23F,
but waned in the group without booster vaccinations.
This result was corroborated by Jackson, Gurtman, van Cleeff,
Jansen et al. (2013), who also found that a booster vaccination with a poly-
saccharide vaccine after a glycoconjugate vaccine gave a greater antibody
response than polysaccharide vaccine alone. Vandecasteele, De Bacquer,
Caluwe, Ombelet, and Van Vlem (2018) found that a conjugate vaccine
was less able to provide a boosting effect on vaccination against
St. pneumoniae in patients previously inoculated with unconjugated vac-
cine, but at the 1-year endpoint all vaccines studied provided acceptable
levels of protection. Conversely, other papers found that booster vaccination
may be more effective if they are glycoconjugate, particularly in populations
immunocompromised by HIV (Lu, O’Halloran, Williams, & Harpaz, 2017).
In addition, in asplenic patients, a difference is also seen depending on the
order of conjugated/unconjugated vaccinations. Rezai, Ghaffari, Mahdavi,
Bahari, and Ala (2017) reported that for asplenic patients, inoculation with
a conjugate vaccine is more effective when it acts as a complimentary
booster vaccine to an unconjugated vaccine, based on IgG titres observed
in each case.
Two other examples of these types of comparisons have been reported.
One report investigated unconjugated versus glycoconjugated cholera vac-
cines (Alam et al., 2014), and found that in a mouse model, unconjugated
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vaccine did not induce the production of IgG. However, IgM production
was comparable between the two vaccine types. Finally, a typhoid vaccine is
currently being studied by Jin et al. (2017). While this trial is ongoing, it
appears that the titre of antibodies is increased using conjugate vaccines, but
that protection levels are essentially the same as comparable unconjugated
vaccine.
Comparison of carriers used in glycoconjugate vaccines
If a polysaccharide antigen can be conjugated to multiple carriers with equal
ease and stability, tests must be performed to determine which compound is
the best at producing an immune response. The following section describes
some of the recent advances in this area.
A range of vaccines have been studied by Gao, Lockyer, Burkin, Crane,
and Bolgiano (2014) to establish common features in their stability, such as
the effect of storage at 2-8°C, −20°C, and repeated freeze/thaw cycles. While
it was found that there were no significant differences in the majority of
cases, storage at −20°C did have a negative impact on the stability of
glycoconjugate vaccines made with CRM197.
A number of studies have been performed on vaccines for Hib. It has
been found by Vella and Ellis (1991) that CRM197 conjugates were poorly
immunogenic in comparison to OMP conjugates. The CRM197 conjugates
only became effective when they were administered along with DT, which
had an adjuvating effect. However, as commercial vaccines were used with
different polysaccharides (OMP-PRP vs CRM197-Hib oligosaccharide) in
this study, the comparison is not direct. The currently licensed Hib vaccine
contains TT, but studies have been performed to challenge its effectiveness
with new vaccinations. When TT and CRM197 were compared as carriers
for PRP (Togashi et al., 2016), no significant differences were found between
the two carriers in terms of their immunogenicity, although the CRM197
conjugate had an increased local reaction. In contrast, it has been found by
Akeda et al. (2018), that CRM197 conferred an increased bactericidal
activity compared to the TT.
In a study on MenACWY conjugated to TT or CRM197 by Bona et al.
(2016), no significant differences were found in the responses between the
two vaccines, despite having subtle variations in polysaccharide composi-
tions in those cases.
Two other studies have made direct comparisons of Hib and meningo-
coccal (Men) vaccines. Otto, Burkin, Amir, Crane, and Bolgiano (2015)
compared their ability to interact with aluminium-based adjuvants rather
than comparing the activity of the vaccines. It was found that AlPO4 was less
able to interact with the vaccines than Al(OH)3, but it was also found that
the degree of interaction varied depending on the protein carrier. TT
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interacted more with the adjuvants than CRM197, regardless of whether the
Hib or MenC polysaccharides were bound. Booy et al. (2015) sought to
make a bivalent vaccine on TT and compared its efficacy to that of Hib-TT
and MenC-CRM197 conjugates. No significant differences in immunogeni-
city were observed between the bivalent vaccine and either of the other
vaccines when considering the relevant disease. Therefore, the bivalent
vaccine may be more useful due to the ease of application, assuming that
production costs are sufficiently low.
Finally, Ali, An, Cui, Haque, and Carbis (2014) compared the effects of
the same basic carrier, DT, on the effectiveness of the O-specific polysac-
charide of S. enterica serovar partyphi A with or without a linker between
the two components. It was found that a higher antibody titre was produced
when the linker was present compared to the simple glycoconjugate.
A number of factors were suggested to be the underlying basis for the
differences observed, including the increased distance between the polysac-
charide and toxoid permitting better access to the antigen sites in the
conjugate with the spacer. However, it is also suggested that the conjugation
event was merely more efficient when the linker is present.
Polysaccharide production
Another important factor that affects vaccine design is the reliable produc-
tion of the individual parts. The protein portion is usually easier to define
and is common between vaccines: the use of proteins in glycoconjugates has
recently been considered in for example Brӧker, Berti, Schneider, and
Vojtek (2017) including some relatively new carriers. However, most pro-
teins are chosen for use in a glycoconjugate based on their historic safety
and strong immunogenicity, and so there have been relatively fewer new
developments in protein production. Therefore, this section reviews only
polysaccharide production.
One method to produce polysaccharides for vaccines is to culture the
relevant bacterium and purify the desired molecules. If this is the goal, it
is first necessary to produce a high yield culture by controlling growth
conditions (Momen, Siadat, Akbari, Ranjbar, & Khajeh, 2016). In the
case of Gram-negative bacteria such as Salmonella (Sa.) enterica serovar
typhi, one suitable method reported involves use of hot phenol to extract
lipopolysaccharide, and core hydrolysis to extract O-antigen to produce
vaccine components (Salman et al., 2015). Another method involves the
breaking down of the extracted CPS of Acinetobacter baumannii into
repeating units using bacteriophage Phi AB6 tailspike protein (Lee et al.,
2017). One scheme by Zanardo et al. (2016) considered the whole
process from start to finish, involving cell separation by tangential
microfiltration, concentration by tangential ultrafiltration, diafiltration
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with SDS, precipitation with trichloroacetic acid, precipitation with
ethanol, and finally anion exchange chromatography. This method was
found to give acceptably pure polysaccharides for use as vaccines for
St. pneumoniae serotype 14. However, as any method that involves
growing a large culture of potentially deadly bacteria is, understandably,
not ideal, alternative methods for in vivo production have been sug-
gested, as we now consider.
One study found that it was possible to transfer the polysaccharide synth-
esis machinery from Men serotype X into Escherichia coli to produce poly-
saccharides with the same properties as the native polysaccharide (Muindi
et al., 2014). Similarly, it has been found for MenX that it is possible to
produce a trisaccharide in E. coli that remains immunogenic, that could be
used rather than the native pentadecasaccharide (Morelli et al., 2014).
Another study found a method of triggering glucosylation of lipopolysac-
charides of Raoulterra terrigena by introducing bacteriophage lysogenic
enzymes to improve the accuracy of antigen production in E. coli (Mann,
Ovchinnikova, King, & Whitfield, 2015). It has also been possible to perform
such transformation on plant cells; the genes for St. pneumoniae CPS from
serotype 3S were transformed into Nicotina tabacum using a pCambia2301
vector with Agrobacterium tumefaciens mediated gene transfer, and the
resulting product was found to be immunogenic in mice (Smith et al., 2014).
Such in vivo production systems are not limited to single serotypes.
A method has been found to produce a trisaccharide common to B and
C serotypes of Cryptococcus neoformans (Guazzelli, Ulc, & Oscarson, 2015),
and CPS for St. pneumoniae serotype 6 that are sufficiently small to react
with St. pneumoniae serotypes 6A, 6B and 6D (Park et al., 2015). Work has
also been performed to produce CPS from four St. pneumoniae serotypes
in vivo in the same E. coli cells (Kay, Yates, Terra, Cuccui, & Wren, 2016).
There has even been some work done to produce a live vaccine for Sa.
enterica serovar typhi that produces the O-antigen from Shigella spp., and is
therefore able to act as a vaccine for two infectious diseases at once
(Dharmasena et al., 2016).
It is also possible to produce polysaccharides in vitro by producing
enzymes that synthesize the polysaccharides. For example, CsaA, CsaB
and CsaC enzymes have all been combined in vitro to produce MenA CPS
that was identical to the native form (Fiebig, Freiberger et al., 2014).
A similar method has been used to produce MenX CPS (Fiebig, Berti
et al., 2014) which has also been conjugated to CRM197 (Fiebig et al., 2016).
Another strategy has been to produce polysaccharides synthetically in
blocks. The exact number can vary, such as a di- and tetra-saccharides
(Budhadev & Mukhopadhyay, 2015), di- and tri-saccharides (Mandal,
2014; Mondal, Liao, Mondal, & Guo, 2015; Si & Misra, 2016), three di-
saccharides (Scott et al., 2016) and two tri-saccharides (Seeberger, Pereira, &
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Govindan, 2017). However, it should be noted that it is possible to compare
assembly methods and one study revealed that linear assembly may be more
effective than block assembly (Dhara & Misra, 2015; Seeberger et al., 2017).
Other methods have been described to produce polysaccharides linearly
such as an automated glycan assembly (Hahm, Hurevich, & Seeberger,
2016) or solid phase synthesis using cyanopialoyl ester as a protecting
group (Geert Volbeda et al., 2017).
For E. coli, methods have been described to generate a pentasaccharide
with a propyl-amino linker at one end to allow easy conjugation to CRM197
(Shang et al., 2015) or use of a heat labile p-methyloxybenzyl protecting
group (Ghosh & Misra, 2016).
To develop a vaccine for Leishmania, glycosyl 1-phosphate was synthe-
sised using fluoridated analogues and solid phase phosphoramidite chem-
istry to make repeating structures (Hara et al., 2018). A repeating
trisaccharide unit for Sta. aureus has been produced, despite the difficult
chemistries involved in alpha-fucosylation and beta-mannosylation, by
using careful choices of protecting groups (Gagarinov, Fang, Liu,
Srivastava, & Boons, 2015).
A number of polysaccharides have been produced to act as vaccines for
different strains of St. pneumoniae. For serotype three strains,
a tetrasaccharide (Parameswarappa et al., 2016) or glucuronic acid-linked
trisaccharide (Weishaupt et al., 2016) has been used. For serotype 6a,
a capsular repeating unit has been produced in a one-pot method despite
the relatively challenging chemistry needed to produce 1,2-cis glycosidic
linkages. Finally, Schumann et al. (2017) have designed an automated glycan
assembly that has produced serotype 8 polysaccharides. They have also
uncovered the minimum epitope needed for protection, and it was con-
jugated to CRM197 for effective protection in rabbits.
Polysaccharides can also be produced that are effective in the treatment of
some cancers. Thomsen-Friedenreich tumour associated carbohydrates
have been produced by 11 step synthesis using D-GalN(3) acceptor carrying
pre-installed alpha-N-hydroxysuccinimidyl moiety, prepared using D-GalN
(3)-thioglycoside donor with N-hydroxysuccinimide (Bourgault, Trabbic,
Shi, & Andreana, 2014).
Conjugate production
The final factor affecting glycoconjugate vaccine design which we would like
to conclude our review with is the actual linking together of the
components.
One method of producing a glycoconjugate vaccine is to use glycosylation
enzymes to transfer polysaccharides onto protein carriers. Typically, this
involves using E. coli as a recombinant expression vector to produce the
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enzymes, since the glycosylation machinery is not native to E. coli. The gene
for Campylobacter jejuni oligosaccharyltransferase PglB was transformed
into E. coli to express PglB and thus perform the glycosylation for
Burkholderia pseudomallei OPS II conjugation to glycoprotein AcrA
(Garcia-Quintanilla, Iwashkiw, Price, Stratilo, & Feldman, 2014). It was
also used to generate a vaccine for Sta. aureus using CPS from serotypes 5
and 8 conjugated to detoxified Pseudomonas aeruginosa exoprotein A,
which was then shown to be protective in mice (Wacker et al., 2014).
A vaccine was made in this way for both Sa. enterica serovar typhi
O-antigen and Sta aureus CPS 5 with various proteins (Ihssen et al.,
2015). Another vaccine developed using this scheme is that for Shigella
flexneri, in which S. flexneri O-polysaccharides were linked to
Pseudomonas aeruginosa EPA-2a (Kämpf et al., 2015).
Perhaps most interestingly, it has also been possible to synthesise
St. pneumoniae polysaccharides covalently liked to CRM197 with multiple
antigens, giving a 13-valent glycoconjugate produced in vivo (Herbert et al.,
2018).
E. coli is not the only possible recombinant host, and as already dis-
cussed can be unsuitable due to its lack of O-linked glycosylation machin-
ery. A glycoconjugate vaccine against Men has been constructed using
a Shigella spp. O-linked glycosylation system (Pan et al., 2016). However, it
is also possible to make a recombinant form using the original pathogen
that expresses introduced O-linked glycosylating enzymes, as demon-
strated using Sa. enterica serovar paratyphi A, in which the
O-polysaccharide was successfully transferred onto an antigenic peptide
(Sun et al., 2018).
Schemes have also been devised for conjugation to non-protein carriers
in vivo. Serotype 14 polysaccharides from St. pneumoniae have been linked
to liposomes, which are highly immunogenic when administered with
a suitable adjuvant (Deng et al., 2014). Similar work has also been performed
for E. coli vaccines using the O-antigen and outer membrane vesicles (Chen
et al., 2016).
It is also possible to perform conjugation in vitro. A vaccine for Bordetella
pertussis has been synthesised by linking oligosaccharides with terminal
trisaccharides to aminooxylated BSA via terminal ketodeoxyoctanate resi-
dues (Robbins et al., 2014).
Conjugation of MenA CPS to TT has been performed by activating
groups to make conjugation more likely (Frasch, Kapre, Lee, & Preaud,
2015). Linking St. pneumoniae and Sa. enterica serovar typhi to DT and TT
respectively can be achieved using an isocyanide-based multicomponent
process with a Ugi-multicomponent reaction (Méndez et al., 2018).
As with the manufacture of individual components, it is important to
ensure that conjugation has occurred successfully and is stable. A number of
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proposals for more effective conjugations have been reported. One such
report by Möginger et al. (2016) finds that the more common binding sites
are at the termini of the protein, suggesting that these bonds form more
easily and should be considered targets for conjugation as they will produce
more stable glycoconjugates.
Adamo et al. (2014) produced a glycan-based antigen from Candida
albicans and conjugated it to CRM197, using tyrosine-directed ligation.
This gave a higher anti-glycan IgG levels than if a lysine residue was used.
A particularly interesting feature of this study was the improvement seen if
directed conjugation was used rather than allowing conjugation to occur at
random, which suggests that reducing the polydispersity may improve
immunogenicity. Conversely, Stefanetti et al. (2014) found that random
conjugation improves the bactericidal activity of antibodies produced in
response to Sa. enterica serovar typhimurium O-antigen conjugated to
CRM197. This may be logical, as if the conjugation always occurred on
the same place in a polysaccharide, very little would be ‘seen’ of the rest of
the antigen after digestion and presentation on the MHC-II.
An experiment was performed to establish if ELISA was a suitable test to
act as quality control in glycoconjugate synthesis. Hib PRP antigens were
conjugated to TT, and ELISA used to assess if the PRP was pure and if the
two components were successfully linked. It was found that ELISA was
suitably precise and cheap for use as a test by others for similar purposes
(Hamidi & Kreeftenberg, 2014).
For Sa. enterica serovar typhi, the Vi-polysaccharide of different lengths
were assessed as an antigen conjugated to a number of different carriers.
Short chain Vi polysaccharide was less able to develop a robust immune
response than long chain, but only when conjugated to DT or CRM197, and
only on primary infection (Arcuri et al., 2017). Quantification of free Vi
polysaccharide has also been used to assess the stability of conjugates
(Giannelli et al., 2017).
Efficacy of a number of factors, in particular the pH, were used to find
a conjugation method for lipopolysaccharide from Vibrio cholerae to either
BSA or TT (Xu et al., 2017). However, such covalent linkages may not be
necessary. It has been found that simply cross-linking a polysaccharide to
a protein matrix may be sufficient to trigger a T cell dependent response
(Thanawastien, Cartee, Griffin, Killeen, & Mekalanos, 2015).
Perspectives
Immunity is complex, but the ability to combine different antigens to
produce beneficial effects is clearly a great advantage for pharmacologists.
It has also borne huge potential for the development of polysaccharide
vaccines, as most polysaccharides (except ZPS) by themselves exhibit poor
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ability to invoke long-term immunity. There are now many examples of
successful long-term, T-cell mediated immunological responses to conju-
gated polysaccharides. However, in the process of glycoconjugation, there
does not appear to be a single ‘best’ carrier or carrier pathway (Figure 1) and
studies suggest that carriers must be tested on a case-by-case basis. Indeed,
based on these previous studies, it seems likely that the best carrier in a given
situation can be chosen for reasons of practicality rather than immunogeni-
city alone. Key elements to consider when choosing a carrier antigen are the
ease with which it can be made reproducibly on an industrial scale, how
stable the final product is, and how safe it is to produce. While the methods
for synthetic polysaccharide production are complex, it is clear that produc-
tion in vitro is much safer than purification from a pathogen culture. As the
repertoire of methods for tailored polysaccharide production, fractionation
and characterisation grows (Harding et al., 2017), it will become easier to
produce efficient, effective and consistently reproducible glycoconjugate
vaccines.
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